The Global Health Innovative Technology Fund (GHIT Fund) of Japan, which in the last two years has funded almost $32 mil...
Singapore: ASLAN Pharmaceuticals, Singapore based biotech company focused on the development of immunotherapies and targ...
Singapore: A team from A*STAR's Institute of Chemical and Engineering Sciences (ICES) and National University Hospital (...
Singapore: Novartis Pharma KK has found no evidence that data on clinical trials for its hypertension drug Diovan had be...
Singapore: Boehringer Ingelheim and Eli Lilly's investigational Type 2 Diabetes (T2D) drug dipeptidyl peptidase-4 (DPP-4...
Singapore: US FDA has accepted Actavis' New Drug Application (NDA) for a progestin-only transdermal contraceptive patch ...
Singapore: Australian drug delivery company, Phosphagenics, has raised $11.45 million of its $15.29 million capital rais...
Singapore: Patrys, Australia's clinical stage biopharmaceutical company, has received approval to progress its phase I/I...
Singapore: Eisai has submitted a marketing authorization application to Japan's Ministry of Health, Labor and Welfare (M...
Singapore: GIDEON (Global Investigation of therapeutic Decisions in hepatocellular carcinoma and of its treatment with s...
Mumbai: Cipla along with the non-profit R&D organization, Drugs for Neglected Diseases initiative (DNDi), revealed t...
Singapore: Boston Strategics Corp (BSC), a clinical-stage drug research and development (R&D) company has signed an ...
Singapore: Associate Professor Matthias Ernst and colleagues from Australia's Walter and Eliza Hall Institute have ident...
Singapore: ASLAN Pharmaceuticals has obtained the global rights to Almirall's DHODH inhibitor, LAS186323, currently in p...
Singapore: Professor Ian Frazer and his team at the University of Queensland, have been awarded grant from Australia's N...
According to the Global Burden of Disease and Risk Factors (World Bank Publications, 2006), infectious diseases are one ...
Singapore: The US Food and Drug Administration has issued a proposal designed to assist companies developing new treatme...
Singapore: India based drug company, Zydus, has initiated Phase III trials of Lipaglyn (Saroglitazar) to evaluate its sa...
